# QL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer

> **NCT07110064** · PHASE2 · RECRUITING · sponsor: **Du Juan** · enrollment: 80 (estimated)

## Conditions studied

- Advance Pancreatic Cancer

## Interventions

- **DRUG:** QL1706+Lenvatinib+AG Regimen

## Key facts

- **NCT ID:** NCT07110064
- **Lead sponsor:** Du Juan
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-03
- **Primary completion:** 2027-08-31
- **Final completion:** 2028-08-31
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07110064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07110064, "QL1706+Lenvatinib+AG Regimen as First-line Treatment for Advanced Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07110064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*